Samuel Waxman is a partner in the Mergers and Acquisitions and Emerging Growth Company practices at Paul
Hastings. He is based in the firm’s New York office.
Mr. Waxman’s practice focuses on mergers and acquisitions, securities offerings, joint ventures, and intellectual property
licenses, with a particular emphasis on companies for whom technology or intellectual property is a key asset. He
also represents venture investment funds and emerging technology companies, and is experienced in structuring and
negotiating angel and venture financing. His clients range in size from Fortune 100 firms to emerging-stage companies
in such diverse industries as pharmaceuticals, medical devices, data security, mobile devices, networking equipment
and biotechnology. Mr. Waxman lectures on intellectual property licensing issues at Cornell Tech, the technology-focused
campus of Cornell University located in New York City.
Venture Capital & Minority Investments
Deerfield Management, in connection with various debt and minority equity investments.
Tuatara Capital, in connection with various debt and minority equity investments.
Ascent Biomedical Ventures, in connection with various debt and minority equity investments.
Orchestra Medical Ventures, in connection with various debt and minority equity investments.
BlackIvy Group, in connection with various debt and minority equity investments.
Deerfield Management, in connection with its early-stage therapeutic research partnerships with
The Broad Institute of MIT and Harvard,
Johns Hopkins University, and
Bridge Medicines, outside general counsel of drug discovery company launched in partnership with Deerfield
Management, Takeda Pharmaceutical Company and Bay City Capital, Memorial Sloan Kettering Cancer Center, The Rockefeller
University and Weill Cornell Medicine.
Mergers & Acquisitions and Joint Ventures
Merck & Co. in connection with various M&A transactions.
Elanco U.S., Inc., a subsidiary of
Eli Lilly and Company, in its acquisition of Boehringer Ingelheim Vetmedica’s U.S. feline, canine and
rabies vaccines portfolio.
Sony Corporation in connection with various M&A transactions.
Nokia Corporation and
Nokia Solutions and Networks (formerly Nokia Siemens Networks) in connection with various M&A transactions.
- Formation counsel to
Sony Corporation's joint patent licensing program for digital television (DTV) and computer display
Atos SE in connection with its acquisition of Anthelios Healthcare Solutions.
HIG Capital in connection with its acquisition of Salary.com.
- Lead counsel to
Intellectual Ventures and
a consortium of 12 of the largest technology companies in the world in connection with the acquisition
and licensing of
Eastman Kodak Company’s digital imaging patent portfolio.
Thomson Reuters in connection with various M&A transactions.
Vector Capital in connection with various M&A and technology licensing transactions.
The Dow Chemical Company in connection with various M&A and technology licensing transactions.
Boston Scientific Corporation in connection with various M&A and technology licensing transactions.
Accolades and Recognitions
- Recognized as a leading M&A, technology and intellectual property lawyer in the Financial Times Innovative Lawyers
Report, Legal 500 and Chambers.
- Intellectual Asset Management’s Patent 1000: The World’s Leading Patent Practitioners stated, “The ‘street-smart’
lawyer has made the most of an outstanding transactional platform at the firm and proved his mettle on some of
the biggest acquisitions/divestitures around.”
- Named to the top “40 Under 40 M&A Professionals” in M&A Advisor (2012)
SPEAKING ENGAGEMENTS AND PUBLICATIONS
- Smarter, Faster, Stronger: A New Suite of VC Model Docs, Law360, May 2018
- NYC: Municipal Benefactor to Life Sciences and Technology Venture Capital, Lexology, Nov 2017
- Plenary Session Moderator, "In Pursuit of Growth, Savings, and Return on Investment: Pharma’s Quest for Innovation
Partnerships", Life Sciences Summit, November 2017
- Guest Lecturer, "Life Sciences Patent Law", NYU School of Law, April 2017
- Resigning From a Board of Directors: Considerations for VC Fund Designees, Lexology, March 2017
- Panelist, Houlihan Lokey 2017 Illiquid Financial Assets Conference, March 2017
- Venture Debt: An Attractive Tool for Start-up Companies, Law360, February 2017
- Making the Grade: Negotiating IP Licenses with Academic Institutions, Licensing Journal, January 2017, Vol. 37 Issue
- Panelist, "Dealmaking 2017: Exploring Academic-Industry Partnerships", New York Pharma Forum, January 2017
- Revisiting the CVR: The Litigation Crucible, Lexology, November 2016
- When Minority Stockholders Take Control: Recent Delaware Cases Shine a Light on Fiduciary Obligations of Controlling
Shareholders, Law360, July 2016
- Legal Health Isn't Easy for Digital Health Companies, TechCrunch. April 2016.
- Post-Closing Fraud Claims in the Acquisition Context: Protecting the Seller, Lexology, February 2016
- Solving The Valuation Puzzle in Life Sciences Transactions: The Pros and Cons of the CVR, The M&A Lawyer, January
- Not Just Refrigerators and Light Bulbs: Connected Vehicles as an Extension of the Internet of Things, Lexology, April
- The Acquisition of IP Assets in Bankruptcy, Intellectual Property Magazine, July/August 2014.
- University of Virginia School of Law, J.D., 2000
- University of Virginia, B.A., 1997, with Distinction